|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||125.00 / 234.93|
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
When there is no real worry, stocks can keep on running, but the rampage in the Nasdaq 100 is not unlike frothy action of the past.
Loxo Oncology, NewLink Genetics and BioCryst Pharmaceuticals were among the biotech movers in premarket trading on Monday.
The Loxo data also represent another advance for precision cancer medicine, in which patients are treated with drugs that target specific tumor mutations, regardless of where the cancer originates.
Here are Friday's top research calls, including upgrades for IberiaBank and Actuant, and downgrades for Kimberly-Clark and Ionis Pharma.
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 723,669 share increase in total short interest for Loxo Oncology, Inc , to 2,684,523, an increase of 36.91% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.